

Pharmacogenetics

HLA-B*5701
DETECTION ASSAY

Description

The British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005) suggest that HLA-B*5701 testing may be able to identify patients with a lower risk of developing abacavir hypersensitivity.¹ The European AIDS Clinical Society guidelines recommend that HLA-B*5701 testing be carried out prior to the commencement of antiretroviral drug treatment.²

Delphic is developing a panel of pharmacogenetic tests for HIV (details on web-site).

¹ The British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005 July 1; 6 (Suppl.2).

² Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. European AIDS Clinical Society (EACS), Madrid, 2007.

Technology

DNA extracted from whole blood sample is tested for the presence or absence of the *5701 gene using a two stage sequence specific Polymerase Chain Reaction assay. Negative results will be reported at this stage. Any suspect positives for the *5701 are then re-tested using DNA sequence based typing (SBT) techniques to exclude genes that are not associated with hypersensitivity and confirm the presence of *5701.

Downloads

The following documents can be downloaded from the Delphic website:

Account Set Up Form
Sample-handling instructions
Test Request Form
Report
Frequently Asked Questions - Scientific
Frequently Asked Questions - Clinical

Delphic Diagnostics
26a Albemarle Street
London W1S 4HY, UK
+44 (0)20 7499 0777
customerservices@delphicdiagnostics.com
www.delphicdiagnostics.com

Laboratory

Delphic Laboratories (Kent) Ltd
1030 Heeley Close
Kent Science Park
Sittingbourne, Kent ME9 8HL
UK

Certification:
BS EN ISO 9001:2000
(Certificate No. FS 56079)
CLIA ID 99D 1060454

Service

Turnaround time: 5-7 days*

* Working days